Cibinqo Approved for Adolescents With Moderate to Severe Atopic Dermatitis
The approval was based on data from previous studies that included 124 adolescent patients, as well as the phase 3 JADE TEEN study.
The approval was based on data from previous studies that included 124 adolescent patients, as well as the phase 3 JADE TEEN study.
Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.
A cohort study of mother and child pairs investigates the association between mode of delivery and atopic dermatitis in children 5 years of age and younger.
The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.
Theoretical annual costs of OTC moisturizer are compared with costs of atopic dermatitis; Medicaid coverage is also reviewed.
A new American Academy of Dermatology (AAD) guideline describes available evidence on comorbidities associated with atopic dermatitis (AD) in adults.
The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled moderate to severe atopic dermatitis.
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
The relationship between atopic disease and serum lipid levels is investigated.
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.